PTC Therapeutics, Inc. PTCT closed lower on Thursday following the company’s decision to withdraw its New Drug Application for Translarna after receiving feedback from the U.S. Food and Drug ...

In a statement, PTC's chief executive, Matthew Klein, said the company had decided to pull the filing for Translarna (ataluren) as a treatment for nonsense mutation DMD after the FDA said it was ...

Why PTC Stock Is Back in Focus After Earnings and New Client Win PTC (PTC) is back on many investors radar after a combination of better than expected quarterly results, higher full year guidance, and ...

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: ...

Wall Street expects a year-over-year increase in earnings on higher revenues when PTC Therapeutics (PTCT) reports results for the quarter ended December 2025. While this widely-known consensus outlook ...

Investing.com -- PTC Inc (NASDAQ:PTC) stock fell 3.8% on Thursday after Google announced a major upgrade to its Gemini 3 Deep Think AI system, potentially challenging PTC’s position in the engineering ...

Detailed price information for Ptc Therapeutics (PTCT-Q) from The Globe and Mail including charting and trades.

CEO Matthew Klein highlighted 2025 as a year of “many significant successes,” citing the initial global approvals and launch of Sephience for PKU as the main highlight. Klein stated, “The global ...